314 related articles for article (PubMed ID: 16427383)
1. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
Poon MC; Zotz R; Di Minno G; Abrams ZS; Knudsen JB; Laurian Y
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S33-6. PubMed ID: 16427383
[TBL] [Abstract][Full Text] [Related]
2. New Insights Into the Treatment of Glanzmann Thrombasthenia.
Poon MC; Di Minno G; d'Oiron R; Zotz R
Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
Poon MC
Vasc Health Risk Manag; 2007; 3(5):655-64. PubMed ID: 18078017
[TBL] [Abstract][Full Text] [Related]
4. NovoSeven (recombinant factor VIIa) for the treatment of bleeding episodes and perioperative management in patients with Glanzmann's thrombasthenia.
Franchini M; Lippi G
Expert Rev Hematol; 2014 Dec; 7(6):733-40. PubMed ID: 25387838
[TBL] [Abstract][Full Text] [Related]
5. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry.
Recht M; Rajpurkar M; Chitlur M; d'Oiron R; Zotz R; Di Minno G; Cooper DL; Poon MC
Am J Hematol; 2017 Jul; 92(7):646-652. PubMed ID: 28370369
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey.
Poon MC; D'Oiron R; Von Depka M; Khair K; Négrier C; Karafoulidou A; Huth-Kuehne A; Morfini M;
J Thromb Haemost; 2004 Jul; 2(7):1096-103. PubMed ID: 15219192
[TBL] [Abstract][Full Text] [Related]
7. Pyelolithotomy in a patient with Glanzmann thrombasthenia and antiglycoprotein IIb/IIIa antibodies: the shortest possible duration of treatment with recombinant activated factor VII and platelet transfusions.
Devecioğlu O; Unüvar A; Anak S; Bilge I; Ander H; Ziylan O
Turk J Pediatr; 2003; 45(1):64-6. PubMed ID: 12718376
[TBL] [Abstract][Full Text] [Related]
8. The international, prospective Glanzmann Thrombasthenia Registry: treatment and outcomes in surgical intervention.
Poon MC; d'Oiron R; Zotz RB; Bindslev N; Di Minno MN; Di Minno G;
Haematologica; 2015 Aug; 100(8):1038-44. PubMed ID: 26001792
[TBL] [Abstract][Full Text] [Related]
9. Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders.
Di Minno G
Blood Rev; 2015 Jun; 29 Suppl 1():S26-33. PubMed ID: 26073366
[TBL] [Abstract][Full Text] [Related]
10. The use of recombinant factor VIla in a primigravida with Glanzmann's thrombasthenia during delivery.
Kale A; Bayhan G; Yalinkaya A; Yayla M
J Perinat Med; 2004; 32(5):456-8. PubMed ID: 15493726
[TBL] [Abstract][Full Text] [Related]
11. Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures.
d'Oiron R; Ménart C; Trzeciak MC; Nurden P; Fressinaud E; Dreyfus M; Laurian Y; Négrier C
Thromb Haemost; 2000 May; 83(5):644-7. PubMed ID: 10823254
[TBL] [Abstract][Full Text] [Related]
12. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues.
Di Minno G; Coppola A; Di Minno MN; Poon MC
Thromb Haemost; 2009 Dec; 102(6):1157-64. PubMed ID: 19967146
[TBL] [Abstract][Full Text] [Related]
13. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature.
Rajpurkar M; Chitlur M; Recht M; Cooper DL
Haemophilia; 2014 Jul; 20(4):464-71. PubMed ID: 24948404
[TBL] [Abstract][Full Text] [Related]
14. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia.
Di Minno G; Zotz RB; d'Oiron R; Bindslev N; Di Minno MN; Poon MC;
Haematologica; 2015 Aug; 100(8):1031-7. PubMed ID: 26001793
[TBL] [Abstract][Full Text] [Related]
15. Glanzmann's thrombasthenia proposed optimal management during surgery and delivery.
Bell JA; Savidge GF
Clin Appl Thromb Hemost; 2003 Apr; 9(2):167-70. PubMed ID: 12812388
[TBL] [Abstract][Full Text] [Related]
16. Acquired Glanzmann's thrombasthenia caused by glycoprotein IIb/IIIa autoantibodies of the immunoglobulin G1 (IgG1), IgG2 or IgG4 subclass: a study in six cases.
Porcelijn L; Huiskes E; Maatman R; de Kreuk A; de Haas M
Vox Sang; 2008 Nov; 95(4):324-30. PubMed ID: 19138263
[TBL] [Abstract][Full Text] [Related]
17. Platelet transfusion in a patient affected by Glanzmann's thrombasthenia with antibodies against GPIIb-IIIa.
Conte R; Cirillo D; Ricci F; Tassi C; Tazzari PL
Haematologica; 1997; 82(1):73-4. PubMed ID: 9107089
[TBL] [Abstract][Full Text] [Related]
18. Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia.
Balci YI; Karabulut A; Kabukcu S; Sari I; Keskin A
Clin Appl Thromb Hemost; 2011 Aug; 17(4):320-2. PubMed ID: 20460355
[TBL] [Abstract][Full Text] [Related]
19. Successful surgery using recombinant factor VIIa for recurrent, idiopathic nonulcer duodenal bleeding in a patient with Glanzmann's thrombasthenia.
van Buuren HR; Wielenga JJ
Dig Dis Sci; 2002 Sep; 47(9):2134-6. PubMed ID: 12353868
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Activated Factor VII (Eptacog Alfa Activated, NovoSeven®) in Patients with Rare Congenital Bleeding Disorders. A Systematic Review on its Use in Surgical Procedures.
Di Minno MND; Ambrosino P; Myasoedova V; Amato M; Ventre I; Tremoli E; Minno AD
Curr Pharm Des; 2017; 23(7):1125-1131. PubMed ID: 28034354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
